Anti-Jo-1
EstablishedAnti-Jo-1 is the most common antisynthetase antibody, defining antisynthetase syndrome (myositis plus interstitial lung disease).
This antibody defines a specific autoimmune condition that combines muscle inflammation, lung scarring, and distinctive rough, cracked skin on the hands. Lung involvement is often the most important part of this condition to manage, sometimes even more than the muscle symptoms.
Anti-Jo-1 (anti-histidyl-tRNA synthetase) antibodies are the most common of the antisynthetase antibodies, defining antisynthetase syndrome, a distinct autoimmune condition combining myositis, interstitial lung disease, and characteristic "mechanic's hands" skin changes.
Positive anti-Jo-1 supports antisynthetase syndrome diagnosis in a patient with muscle weakness and/or interstitial lung disease, and interstitial lung disease is often the dominant, most prognostically important feature, sometimes presenting before or without significant muscle involvement.
Measured via immunoassay (ELISA) or line blot as part of a myositis-specific antibody panel; anti-Jo-1 is one of several antisynthetase antibodies (others include anti-PL-7, anti-PL-12, anti-EJ, anti-OJ) that collectively define the syndrome, though anti-Jo-1 is by far the most commonly encountered.
Confirmed antisynthetase syndrome, especially with significant lung involvement, typically requires combination immunosuppression (corticosteroids plus a steroid-sparing agent) and close pulmonary monitoring, since interstitial lung disease severity, not muscle weakness, is usually the primary driver of long-term prognosis.
Interstitial lung disease, not muscle weakness, is usually the primary driver of long-term prognosis in this syndrome.
- General rheumatology reference literature on anti-Jo-1 and antisynthetase syndrome diagnosis and management.